Clinical trials: Vaso-occlusive Crisis
Sickle Cell
Diastolic Dysfunction in Sickle Cell Disease During Vaso-occlusive Crisis
This study is designed to investigate the presence and absence of abnormal heart muscle contractions during sickle cell crises. You will be asked to do echocardiography during and after your admission to the hospital.
- Trial name
- NCT01683968
- Where
- Saudi Arabia
- Volunteers
- 216 people
- Sponsor
- King Abdullah International Medical Research Center
Sickle Cell Disease, Sickle Cell Crisis
Lidocaine Intravenous in the Emergency Department For Sickle Cell Crisis
Sickle cell crisis continues to be a frequent presentation to emergency departments. Patients presenting will often require immediate treatment for their pain and often times this will include opioids.
- Conditions
- Sickle Cell Disease, Sickle Cell Crisis, Pain, Acute
- Trial name
- RELIEF-SCC (NCT04614610)
- Testing
- Lidocaine Iv
- Where
- 3 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Community Medical Center, Toms River, NJ
Sickle Cell Disease
Evaluation of Repeat Administration of Purified Poloxamer 188
The purpose of this study is to evaluate the safety of repeat administration of MST-188 during vaso-occlusive crisis of sickle cell disease.
- Trial name
- EPIC-E (NCT02449616)
- Testing
- MST-188
- Where
- 9 sites in United States
- Volunteers
- 16 people
- Sponsor
- Mast Therapeutics, Inc.
Sickle Cell Disease
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult…
- Trial name
- SPARKLE (NCT06439082)
- Testing
- Crizanlizumab
- Where
- 36 sites in United States, Brazil and 3 more
- Volunteers
- 354 people
- Sponsor
- Novartis Pharmaceuticals
Hemoglobin SC Disease, Sickle Cell Anemia
A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling Disorders
Sickle cell anemia is a genetic disorder that results from a single nucleotide substitution in codon 6 of the beta-globin gene which, in the homozygous state, produces an abnormal hemoglobin that is prone to polymer formation…
- Trial name
- NCT00005783
- Testing
- Recombinant-methionyl human stem cell factor
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Sickle Cell Disease
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
The purpose of this study was to determine whether the investigational drug SelG1 when given to sickle cell disease patients either taking or not taking hydroxyurea was effective in preventing or reducing the occurrence of pain…
- Trial name
- SUSTAIN (NCT01895361)
- Testing
- SelG1
- Where
- 56 sites in United States, Brazil and 1 more
- Volunteers
- 198 people
- Sponsor
- Reprixys Pharmaceutical Corporation
Sickle Cell Disease
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered subcutaneously (SC) at the maximum tolerated dose (MTD) in adult participants with…
- Trial name
- NCT07224360
- Testing
- Anumigilimab
- Where
- 38 sites in United States, Belgium and 5 more
- Volunteers
- 63 people
- Sponsor
- CSL Behring
Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
The purpose of this research is to see if ketamine is effective and safe in treating children and young adults with sickle cell disease experiencing sickle cell related pain.
- Conditions
- Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease, Ketamine Infusion, Pain Management
- Trial name
- NCT07369024
- Testing
- Sub-dissociative Ketamine Infusion
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Mohsen Saidinejad
Sickle Cell Disease, Vaso-occlusive Crisis
Outcomes of Vaso-occlusive Crisis in Pediatric Sickle Cell Disease
This study aims to assess the incidence and clinical outcomes of vaso-occlusive crises in pediatric patients with sickle cell disease. Data will be collected and analyzed to identify risk factors and related complications.
- Trial name
- NCT07200869
- Testing
- No intervention
- Where
- Egypt
- Volunteers
- 25 people
- Sponsor
- Assiut University
Sickle Cell Disease
Virtual Reality for SCD VOC
This randomized pilot study will evaluate the feasibility, tolerability, and preliminary analgesic effect of headset-based virtual reality (VR) interventions for adults with sickle cell disease (SCD) experiencing vaso-occlusive…
- Trial name
- RELIEVE-SCD (NCT07674277)
- Testing
- Passive Immersive 3D Virtual Reality, Active Immersive Interactive 3D Virtual Reality
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Maryland, Baltimore
Sickle Cell Disease
A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis
This study is being done to learn more about a possible new treatment for pain episodes (called vaso-occlusive crises or VOCs) in children, teens, and young adults with sickle cell disease (SCD).
- Trial name
- NCT06989567
- Testing
- L-citrulline
- Where
- 6 sites in United States
- Volunteers
- 120 people
- Sponsor
- Asklepion Pharmaceuticals, LLC
Sickle Cell Disease (SCD)
An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients
Sickle cell disease (SCD) is a genetic blood disorder. Crizanlizumab is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in patients with SCD aged 16 years and older.
- Trial name
- NCT04662931
- Testing
- crizanlizumab
- Where
- 7 sites in India
- Volunteers
- 140 people
- Sponsor
- Novartis Pharmaceuticals
Vaso-occlusive Crisis, Reduction in Hospitalizations
Apixaban in Patients With Sickle Cell Disease
In patients with SCD, the use of low dose anticoagulation as an outpatient may lead to a significant decrease in morbidity and as a result, decrease healthcare utilization and costs.
- Conditions
- Vaso-occlusive Crisis, Reduction in Hospitalizations, Sickle Cell Disease
- Trial name
- NCT02179177
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Nirmish Shah
Sickle Cell Disease
High-flow Oxygen for Vaso-occlusive Pain Crisis
Sickle cell disease (SCD) is characterized by recurrent vaso-occlusive pain crisis (VOC), which may evolve to acute chest syndrome (ACS), the most common cause of death among adult patients with SCD.
- Trial name
- OSONE (NCT03976180)
- Testing
- Stadard low-flow oxygen, HFNO with low FiO2 (21%-30%), HFNO with intermediate FiO2 (50%)
- Where
- France
- Volunteers
- 350 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sickle Cell Disease, Vaso-occlusive Crisis
Sex Hormones and Inflammatory Biomarkers in Patients With Sickle Cell Disease
This study aims to characterize sex differences in the pathophysiology of vaso-occlusive crises (VOC) occurring among individuals with sickle cell disease (SCD).
- Trial name
- NCT06345638
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- University of Pennsylvania
Sickle Cell Disease, Sickle Cell Crisis
Optimal Timing of Ketamine Initiation for SCD Pain
The goal of this clinical trial is to learn if the use of early ketamine decreases the chance of admission to the hospital in patients with sickle cell disease presenting with pain.
- Trial name
- NCT07450430
- Testing
- Ketamine hydrochloride injection
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Boston Children's Hospital
Sickle Cell Disease
Prevention of Vaso-occlusive Painful Crisis by Using Omega-3 Fatty Acid Supplements
140 SCD patients [70 on Hydroxyurea] will receive Omega-3 capsules whereas another 140 SCD patients [70 on Hydroxyurea] will receive placebo and will be recruited from the Sultan Qaboos University Hospital [SQUH] haematology…
- Trial name
- OM3FA (NCT02525107)
- Testing
- Omega-3 capsules
- Where
- Oman
- Volunteers
- 280 people
- Sponsor
- Sultan Qaboos University
Sickle Cell Disease
Implication of the Oxydative Stress in the Pathophysiology of Sickle Cell Anemia:
Despite important advances in the current understanding of sickle cell vaso-occlusion, the basis of its control and prevention remain partially unknown.
- Trial name
- STRESS (NCT03368924)
- Testing
- SCA patients (SS genotype)
- Where
- Guadeloupe
- Volunteers
- 38 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Sickle Cell Anemia
Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease
OBJECTIVES: I. Assess the efficacy of poloxamer 188 in reducing the duration of painful vaso-occlusive crisis in patients with sickle cell disease. II.
- Trial name
- NCT00004408
- Testing
- poloxamer 188
- Volunteers
- 300 people
- Sponsor
- Mast Therapeutics, Inc.
Sickle Cell-hemoglobin SS Disease, Vaso-occlusive Crisis
Non Invasive Positive Pressure Ventilation for Prevention of Acute Chest Syndrome in Sickle Cell Disease
Acute chest syndrome is a severe respiratory complication of sickle cell disease. The standard prevention of this dangerous complication is spirometry in wich patient is required to take deep breaths trough a little device…
- Trial name
- VPACS (NCT01501643)
- Testing
- Non invasive positive pressure ventilation, Spirometry
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris